NCT03301649View on ClinicalTrials.gov

Clinical Endpoint Study of Ivermectin 0.5% Lotion

PHASE3CompletedINTERVENTIONAL
Enrollment

905

Participants

Timeline

Start Date

October 7, 2017

Primary Completion Date

March 12, 2018

Study Completion Date

March 12, 2018

Conditions
Head Lice
Interventions
DRUG

Generic Ivermectin Lotion 0.5%

Topical lotion, generic formulation of the brand product.

DRUG

Sklice® (Ivermectin) Lotion 0.5%

Topical lotion, brand product.

DRUG

Vehicle Lotion

Topical lotion, placebo. Has no active ingredient.

Trial Locations (1)

33134

Site 1, Miami

Sponsors

Lead Sponsor

Actavis Inc.
All Listed Sponsors
collaborator

Teva Pharmaceuticals USA

INDUSTRY

lead

Actavis Inc.

INDUSTRY

NCT03301649 - Clinical Endpoint Study of Ivermectin 0.5% Lotion | Biotech Hunter | Biotech Hunter